Single and Multiple Ascending Dose Study of AMG 378 in Healthy Participants

Exclusion Criteria

• •History of malignancy of any type.
• •History of esophageal, gastric, or duodenal ulceration prior to screening visit.
• •Evidence of active bacterial, viral, fungal or parasitic infections within the last 30 days prior to study Day 1.
• •History or evidence of clinically significant arrhythmia at screening, or Day 1 ECG.
• •A QT interval corrected for heart rate (HR) based on the Fridericia method (QTcF) interval \> 450 ms in all participants regardless of biological sex or history/evidence of long QT syndrome at screening or study Day -1.
• •Positive results for human immunodeficiency virus (HIV) antibodies, HIV antigen, hepatitis B surface antigen, hepatitis B core antibody, or hepatitis C virus ribonucleic acid (RNA) at screening.
• •History of active tuberculosis (TB) infection, current symptoms concerning for active TB, or positive or indeterminate interferon gamma release assay (IGRA).
• •Positive test for drugs, cotinine (tobacco use) or alcohol use at screening or on Day -1.
• •Sexually active female participants of childbearing potential unwilling to use 2 protocol specified highly effective methods of contraception during treatment and for an additional 30 days after the last dose of investigational product.
• •Alcohol consumption from 48 hours prior to study Day 1.
• •Use of tobacco- or nicotine-containing products within 6 months prior to study Day 1.